Cancer References

Sept. 13, 2004 - Natural Products Industry INSIDER
"Cancer" References

1. Keck AS, Finley JW. "Cruciferous vegetables: cancer protectivemechanisms of glucosinolate hydrolysis products and selenium." IntegrCancer Ther. 3, 1:5-12, 2004.

2. Johnson IT. "New approaches to the role of diet in the prevention ofcancers of the alimentary tract." Mut Res. 551, 1-2:9-28, 2004. www.mutationresearch.com

3. Hara M et al. "Cruciferous vegetables, mushrooms and gastrointestinalcancer risks in a multicenter, hospital-based case-control study in Japan."Nutr Cancer. 46, 2:138-47, 2003. www.erlbaum.com/Journals/journals/NC/nc.htm

4. Hu J et al. "Diet and vitamin or mineral supplements and risk ofrenal cell carcinoma in Canada." Cancer Causes Control. 14,8:705-14, 2003. www.kluweronline.com/issn/0957-5243/contents

5. Klaunig JE, Kamendulis LM. "The role of oxidative stress incarcinogenesis." Annu Rev Pharmacol Toxicol. 44:239-67, 2004. http://nutr.annualreviews.org/

6. Moller P, Loft S. "Interventions with antioxidants and nutrients inrelation to oxidative DNA damage and repair." Mut Res. 551,1-2:79-89, 2004. www.mutationresearch.com

7. Seifried HE et al. "The antioxidant conundrum in cancer." CancerRes. 63, 15:4295-8, 2003. http://cancerres.aacrjournals.org

8. Prasad KN. "Antioxidants in cancer care: when and how to use them asan adjunct to standard and experimental therapies." Expert RevAnticancer Ther. 3, 6:903-15, 2003.

9. Mantovani G et al. "The impact of different antioxidant agents aloneor in combination on reactive oxygen species, antioxidant enzymes and cytokinesin a series of advanced cancer patients at different sites: correlation withdisease progression." Free Rad Res. 37, 2:213-23, 2003. www.tandf.co.uk/journals

10. Drisko JA, Chapman J, Hunter VJ. "The use of antioxidants withfirst-line chemotherapy in two cases of ovarian cancer." J Am Coll Nutr.22, 2:118-23, 2003. www.am-coll-nutr.org/jacn/jacn.htm

11. Block KI, Mead MN. "Vitamin C in alternative cancer treatment:historical background." Integr Cancer Ther. 2, 2:147-54, 2003.

12. Wenzel U et al. "Ascorbic acid suppresses drug-induced apoptosis inhuman colon cancer cells by scavenging mitochondrial superoxide anions." Carcinogenesis.25, 5:703-12, 2004. http://carcin.oupjournals.org

13. Nissen SB et al. "Intake of vitamins A, C and E from diet andsupplements and breast cancer in postmenopausal women." Cancer CausesControl. 14, 8:695-704, 2003. www.kluweronline.com/issn/0957-5243/contents

14. Gunawardena K, Campbell LD, Meikle AW. "Combination therapy withvitamins C plus E inhibits survivin and human prostate cancer cell growth."Prostate. 59, 3:319-27, 2004.

15. Fleischauer AT, Simonsen N, Arab L. "Antioxidant supplements andrisk of breast cancer recurrence and breast cancer-related mortality amongpostmenopausal women." Nutr Cancer. 46, 1:15-22, 2003. www.erlbaum.com/Journals/journals/NC/nc.htm

16. Sung L et al. "Vitamin E: the evidence for multiple roles incancer." Nutr Cancer. 46, 1:1-14, 2003. www.erlbaum.com/Journals/journals/NC/nc.htm

17. Campbell S et al. "Development of gamma (gamma)-tocopherol as acolorectal cancer chemopreventive agent." Crit Rev Oncol Hematol.47, 3:249-59, 2003.

18. Huang HY et al. Prospective study of antioxidant micronutrients in theblood and the risk of developing prostate cancer. Am J Epidemiol. 175,4:335-44, 2003. www.aje.oupjournals.org.

19. Virtamo J et al. "Incidence of cancer and mortality followingalpha-tocopherol and beta-carotene supplementation: a postinterventionfollow-up." JAMA. 290, 4:476-85, 2003. www.jama.com

20. Rodriguez C et al. "Vitamin E supplements and risk of prostatecancer in U.S. men." Cancer Epidemiol Biomarkers Prev. 13, 3:378-82,2004. http://cebp.aacrjournals.org/

21. Takagi H et al. "Pilot clinical trial of the use of alpha-tocopherolfor the prevention of hepatocellular carcinoma in patients with livercirrhosis." Int J Vitam Nutr Res. 73, 6:411-5, 2003.

22. Jacobs EJ et al. "Vitamin C and vitamin E supplement use and bladdercancer mortality in a large cohort of U.S. men and women." Am JEpidemiol. 156, 11:1002-10, 2002. www.aje.oupjournals.org.

23. Taylor PR et al. "Prospective study of serum vitamin E levels andesophageal and gastric cancers." J Natl Cancer Inst. 95, 18:1414-6,2003. http://jncicancerspectrum.oupjournals.org/jnci.

24. Neuzil J. "Vitamin E succinate and cancer treatment: a vitamin Eprototype for selective antitumor activity." Br J Cancer. 89,10:1822-6, 2003. www.nature.com/bjc

25. Dalen H, Neuzil J. "Alpha-tocopheryl succinate sensitizes a Tlymphoma cell line to TRAIL-induced apoptosis by suppressing NF-kappaBactivation." Br J Cancer. 88, 1:153-8, 2003. www.nature.com/bjc

26. Shun MC et al. "Pro-apoptotic mechanisms of action of a novelvitamin E analog (alpha-TEA) and a naturally occurring form of vitamin E(delta-tocotrienol) in MDA-MB-435 human breast cancer cells." NutrCancer. 48, 1:95-105, 2004. www.erlbaum.com/Journals/journals/NC/nc.htm

27. McIntyre BS et al. "Antiproliferative and apoptotic effects oftocopherols and tocotrienols on preneoplastic and neoplastic mouse mammaryepithelial cells." Proc Soc Exp Biol Med. 224:292-301, 2002.

28. Guthrie N et al. Inhibition of proliferation of estrogenreceptor-negative MDA-MB-435 and -positive MCF-7 human breast cancer cells bypalm oil tocotrienols and tamoxifen, alone and in combination. J Nutr.127, 3:544S-548S, 1997. www.nutrition.org.

29. Venkateswaren V, Fleshner NE, Klotz LH. "Synergistic effect ofvitamin E and selenium in human prostate cancer cell lines." ProstateCancer Prostatic Dis. 7, 1:54-6, 2004.

30. Li H. "A prospective study of plasma selenium levels and prostatecancer risk." J Natl Cancer Inst. 96, 9:696-703, 2004. http://jncicancerspectrum.oupjournals.org/jnci.

31. Duffield-Lillico AJ et al. Selenium supplementation, baseline plasmaselenium status and incidence of prostate cancer: an analysis of the completetreatment period of the Nutritional Prevention of Cancer Trial. BJU Int. 91,7:608-12, 2003.

32. Whanger PD. "Selenium and its relationship to cancer: an updatedagger." Br J Nutr. 91, 1:11-28, 2004. www.cabi-publishing.org/journals/bjn

33. Waters DJ et al. "Making sense of sex and supplements: differencesin the anticarcinogenic effects of selenium in men and women." Mut Res.551, 1-2:91-107, 2004. www.mutationresearch.com

34. Moyad MA. "Zinc for prostate disease and other conditions: a littleevidence, a lot of hype and a significant potential problem." Urol Nurs.24, 1:49-52, 2004. www.ahsl.arizona.edu/journals/ejrnl_gateway.cfm?name=Urologic%20Nursing

35. Costello LC et al. "Role of zinc in the pathogenesis and treatmentof prostate cancer: critical issues to resolve." Prostate Cancer ProstatDis. 7, 2:111-7, 2004.

36. Feng P et al. "Effect of zinc on prostatic tumorigenicity in nudemice." Ann NY Acad Sci. 1010:316-20, 2003. www.nyas.org/publications/annals/

37. Stover PJ. "Physiology of folate and vitamin B12 in health anddisease." Nutr Rev. 62, 6 Pt. 2:S3-12, 2004. www.ilsi.org/publications/reviews.html

38. Kim YI. "Folate, colorectal carcinogenesis and DNA methylation:lessons from animal studies." Environ Mol Mutagen. 44, 1:10-25,2004.

39. Choi SW et al. "Vitamin B-12 deficiency induces anomalies of basesubstitution and methylation in the DNA of rat colonic epithelium." JNutr. 134, 4:750-5, 2004. www.nutrition.org

40. Zhang SM. "Role of vitamins in the risk, prevention and treatment ofbreast cancer." Curr Opin Obstet Gynecol. 16, 1:19-25, 2004. www.co-obgyn.com

41. Sellers TA et al. "Dietary folate intake, alcohol and risk of breastcancer in a prospective study of postmenopausal women." Epidemiology.12, 4:420-8, 2001. www.epidem.com

42. Hernandez BY et al. "Diet and premalignant lesions of the cervix:evidence of a protective role for folate, riboflavin, thiamin and vitaminB12." Cancer Causes Control. 14, 9:859-70, 2003. www.kluweronline.com/issn/0957-5243/contents

43. Chew BP, Park JS. "Carotenoid action on the immune response." JNutr. 134, 1:257S-61S, 2004. www.nutrition.org

44. Castelao JE et al. "Carotenoids/vitamin C and smoking-relatedbladder cancer." Int J Cancer. 110, 3:417-23, 2004. www3.interscience.wiley.com

45. Nkondjock A, Ghadirian P. "Dietary carotenoids and the risk of coloncancer: case-control study." Int J Cancer. 110, 1:110-6, 2004. www3.interscience.wiley.com

46. Wu K et al. "Plasma and dietary carotenoids, and the risk ofprostate cancer: a nested case-control study." Cancer EpidemiolBiomarkers Prev. 13, 2:260-9, 2004. http://cebp.aacrjournals.org/

47. Binns CW, LJ LJ, Lee AH. "The relationship between dietarycarotenoids and prostate cancer risk in Southeast Chinese men." Asia PacJ Clin Nutr. 13, Suppl:S117, 2004.

48. Etminan M, Takkouche B, Caamano-Isorna F. "The role of tomatoproducts and lycopene in the prevention of prostate cancer: a meta-analysis ofobservational studies." Cancer Epidemiol Biomarkers Prev. 13,3:340-5, 2004. http://cebp.aacrjournals.org/

49. Hwang ES, Bowen PE. "Can the consumption of tomatoes or lycopenereduce cancer risk?" Integr Cancer Ther. 1, 2:121-32, 2002.

50. Kucuk O et al. Effects of lycopene supplementation in patients withlocalized prostate cancer. Exp Biol Med (Maywood). 227, 10:881-5, 2002. www.ebmonline.org.

51. Nishino H et al. American Academy of Cancer Research.

52. Jyonouchi H et al. "Antitumor activity of astaxanthin and its modeof action." Nutr Cancer. 36, 1:59-65, 2000. www.erlbaum.com/Journals/journals/NC/nc.htm

53. Kurihara H et al. "Contribution of the antioxidative property ofastaxanthin to its protective effect on the promotion of cancer metastasis inmice treated with restraint stress." Life Sci. 70, 21:2509-20, 2002.www.sciencedirect.com/science/journal/00243205

54. Paolini M et al. Beta-carotene: a cancer chemopreventive agent or aco-carcinogen? Mut Res. 543, 3:195-200, 2003. www.mutationresearch.com.

55. Baron JA et al. "Neoplastic and antineoplastic effects ofbeta-carotene on colorectal adenoma recurrence: results of a randomizedtrial." J Natl Cancer Inst. 95, 10:717-22, 2003. http://jncicancerspectrum.oupjournals.org/jnci.

56. Palozza P et al. Beta-carotene regulates NF-kappaB DNA-binding activityby a redox mechanism in human leukemia and colon adenocarcinoma cells. J Nutr.133, 2:381-8, 2003. www.nutrition.org.

57. Jones DJ et al. "Characterization of metabolites and the putativecancer chemopreventive agent quercetin and their effect on cyclo-oxygenaseactivity." Br J Cancer. Epub ahead of print; Aug. 3, 2004. www.nature.com/bjc

58. Indap MA, Barkume MS. "Efficacies of plant phenolic compounds onsodium butyrate induced anti-tumour activity." Indian J Exp Biol.41, 8:861-4, 2003.

59. Wildman RE (ed). Handbook of Nutraceuticals and Functional Foods.113-26, 2001. CRC Press.

60. Manthey JA, Guthrie N. "Antiproliferative activities of citrusflavonoids against six human cancer cell lines." J Agric Food Chem.50:5837-43, 2002. http://pubs.acs.org/journals/jafcau

61. Manthey JA, Guthrie N, Grohmann K. "Biological properties of citrusflavonoids pertaining to cancer and inflammation." Curr Medicinal Chem.8:135-53, 2001.

62. Guthrie N et al. "Inhibition of human breast cancer cells by citruslimonoids." ACS Symposium Series, 2000.

63. Bagchi D et al. "Anti-angiogenic, antioxidant and anti-carcinogenicproperties of a novel anthocyanin-rich berry extract formula." Biochemistry(Mosc). 69, 1:75-80, 2004.

64. Roy S et al. "Anti-angiogenic property of edible berries." FreeRad Res. 36, 9:1023-31, 2002. www.tandf.co.uk/journals

65. Singh RP et al. "Grape seed extract inhibits advanced human prostatetumor growth and angiogenesis and upregulates insulin-like growth factor bindingprotein-3." Int J Cancer. 108, 5:733-40, 2004. www3.interscience.wiley.com

66. Agarwal C, Singh RP, Agarwal R. "Grape seed extract inducesapoptotic death of human prostate carcinoma DU145 cells via caspases activationaccompanied by dissipation of mitochondrial membrane potential and cytochrome crelease." Carcinogenesis. 23, 11:1869-76, 2002. http://carcin.oupjournals.org

67. Dhanalakshmi S, Agarwal R, Agarwal C. "Inhibition of NF-kappaBpathway in grape seed extract-induced apoptotic death of human prostatecarcinoma DU145 cells." Int J Oncol. 23, 3:721-7, 2003. www.erlbaum.com/Journals/journals/NC/nc.htm

68. Tyagi A, Agarwal R, Agarwal C. "Grape seed extract inhibitsEGF-induced and constitutively active mitogenic signaling but activates JNK inhuman prostate carcinoma DU145 cells: possible role in antiproliferation andapoptosis." Oncogene. 22, 9:1302-16, 2003.

69. Cheng Y et al. "Inhibition of nicotine-DNA adduct formation in miceby six dietary constituents." Food Chem Tox. 41, 7:1045-50, 2003. www.elsevier.nl/locate/foodchemtox

70. Bagchi M et al. "Protective effects of antioxidants againstsmokeless tobacco-induced oxidative stress and modulation of Bc1-2 and p53 genesin human oral keratinocytes." Free Rad Res. 35, 2:181-94, 2001. www.tandf.co.uk/journals

71. Stewart JR, Artime MC, O'Brian CA. "Resveratrol: a candidatenutritional substance for prostate cancer prevention." J Nutr. 133,7 Suppl:2440S-43S, 2003. www.nutrition.org

72. Fu ZD et al. "[Chemopreventive effect of reseveratrol tocancer.]" Ai Zheng. 23, 8:869-73, 2004.

73. Schneider Y et al. "(Z)-3,5,4'-Tri-O-methyl-resveratrol inducesapoptosis in human lymphoblastoid cells independently of their p53 status."Cancer Lett. 211, 2:155-61, 2004. www.elsevier.com/locate/canlet

74. Zhou HB et al. "Resveratrol induces apoptosis in human esophagealcarcinoma cells." World J Gastroenterol. 9, 3:408-11, 2003.

75. Huynh HT, Teel RW. "Selective induction of apoptosis in humanmammary cancer cells (MCF-7) by Pycnogenol." Anticancer Res. 20,4:2417-20, 2000. www.geocities.com/Athens/Rhodes/8729/iiar/iiar.htm

76. Peng Q, Wei Z, Lau BH. "Pycnogenol inhibits tumor necrosisfactor-alpha-induced nuclear factor kappa B activation and adhesion moleculeexpression in human vascular endothelial cells." Cell Mol Life Sci.57, 5:834-41, 2000.

77. Park OJ, Surh YJ. "Chemopreventive potential of epigallocatechingallate and genistein: evidence from epidemiological and laboratorystudies." Toxicol Lett. 150, 1:43-56, 2004. www.sciencedirect.com/science/journal/03784274

78. Mu LN et al. "[Study on the protective effect of green tea ongastric, liver and esophageal cancers.]" Zhonghua Yu Fang Yi Xue Za Zhi.37, 3:171-3, 2003.

79. Binns CW et al. "Green tea consumption enhances survival ofepithelial ovarian cancer patients." Asia Pac J Clin Nutr. 13,Suppl:S116, 2004.

80. Saffair Y, Sadrzadeh SM. "Green tea metabolite EGCG protectsmembranes against oxidative damage in vitro." Life Sci. 74,12:1513-8, 2004. www.sciencedirect.com/science/journal/00243205

81. Wei DZ et al. "Inhibition of liver cancer cell proliferation andmigration by a combination of (-)-epigallocatechin-3-gallate and ascorbicacid." J Chemother. 15, 6:591-5, 2003.

82. Borska S et al. "Induction of apoptosis by EGCG in selected tumourcell lines in vitro." Folia Histochem Cytobiol. 41, 4:229-32, 2003.

83. Yokoyama M et al. "The tea polyphenol, (-)-epigallocatechin gallateeffects on growth, apoptosis and telomerase activity in cervical celllines." Gynecol Oncol. 92, 1:197-204, 2004. www.elsevier.com/locate/issn/0090-8258

84. Anh WS et al. "A major constituent of green tea, EGCG, inhibits thegrowth of a human cervical cancer cell line, CaSki cells, through apoptosis,G(1) arrest and regulation of gene expression." DNA Cell Biol. 22,3:217-24, 2003.

85. Mittal A et al. "EGCG down-regulates telomerase in human breastcarcinoma MCF-7 cells, leading to suppression of cell viability and induction ofapoptosis." Int J Oncol. 24, 3:703-10, 2004. www.erlbaum.com/Journals/journals/NC/nc.htm

86. Zhou JR et al. "Soy phytochemicals and tea bioactive componentssynergistically inhibit androgen-sensitive human prostate tumors in mice." JNutr. 133, 2:516-21, 2003. www.nutrition.org

87. Zhou JR et al. "Combined inhibition of estrogen-dependent humanbreast carcinoma by soy and tea bioactive components in mice." Int JCancer. 108, 1:8-14, 2004. www3.interscience.wiley.com

88. Wu AH et al. "Green tea and risk of breast cancer in AsianAmericans." Int J Cancer. 106, 4:574-9, 2003. www3.interscience.wiley.com

89. Yan L, Li D, Yee JA. "Dietary supplementation with isolated soyprotein reduces metastasis of mammary carcinoma cells in mice." Clin ExpMetastasis. 19, 6:535-40, 2002. www.kluweronline.com/issn/0262-0898/contents

90. Jakes RW et al. "Mammographic parenchymal patterns and self-reportedsoy intake in Singapore Chinese women." Cancer Epidemiol Biomarkers Prev.11, 7:608-13, 2002. http://cebp.aacrjournals.org/

91. Sarkar FH, Li Y. "Soy isoflavones and cancer prevention." CancerInvest. 21, 5:744-57, 2003.

92. Peeters PH et al. "Phytoestrogens and breast cancer risk: Review ofthe epidemiological evidence." Breast Cancer Res Treat. 77,2:171-83, 2003. http://cancerres.aacrjournals.org

93. Wood CE et al. "Breast and uterine effects of soy isoflavones andconjugated equine estrogens in postmenopausal female monkeys." J ClinEndocrinol Metab. 89, 7:3462-8, 2004. http://jcem.endojournals.org

94. Hussain M et al. "Soy isoflavones in the treatment of prostatecancer." Nutr Cancer. 47, 2:111-7, 2003. www.erlbaum.com/Journals/journals/NC/nc.htm

95. Kumar NB et al. "The specific role of isoflavones in reducingprostate cancer risk." Prostate. 59, 2:141-7, 2004.

96. Jarred RA et al. "Induction of apoptosis in low- to moderate-gradehuman prostate carcinoma by red clover-derived dietary isoflavones." CancerEpidemiol Biomarkers Prev. 11, 12:1689-96, 2002. http://cebp.aacrjournals.org/

97. Atkinson C et al. "Red clover-derived isoflavones and mammographicbreast density: a double blind, randomized, placebo-controlled trial." BreastCancer Res. 6, 3:R170-9, 2004. http://breast-cancer-research.com/

98. Powles T. "Isoflavones and women's health." Breast CancerRes. 6, 3:140-2, 2004. http://breast-cancer-research.com/

99. McCann SE et al. "Dietary lignan intakes and risk of pre- andpostmenopausal breast cancer." Int J Cancer. 111, 3:440-3, 2004.www3.interscience.wiley.com

100. Linseisen J et al. "Dietary phytoestrogen intake and premenopausalbreast cancer risk in a German case-control study." Int J Cancer.110, 2:284-90, 2004. www3.interscience.wiley.com

101. McCann SE et al. "The risk of breast cancer associated with dietarylignans differs by CYP17 genotype in women." J Nutr. 132,10:3036-41, 2002. www.nutrition.org

102. Chen J et al. "Exposure to flaxseed or its purified lignan duringsuckling inhibits chemically induced rat mammary tumorigenesis." ExpBiol Med (Maywood). 228, 8:951-8, 2003. www.ebmonline.org

103. Chen J, Stavro PM, Thompson LU. "Dietary flaxseed inhibits humanbreast cancer growth and metastasis and downregulates expression of insulin-likegrowth factor and epidermal growth factor receptor." Nutr Cancer.43, 2:187-92, 2002. www.erlbaum.com/Journals/journals/NC/nc.htm

104. Thompson Lu et al. "Biological effects of dietary flaxseed inpatients with breast cancer." Breast Cancer Res Treat. 64:50, 2000. http://cancerres.aacrjournals.org

105. Goss et al. "Effects of dietary flaxseed in women with cyclicalmastalgia." Breast Cancer Res Treat. 64:49, 2000. http://cancerres.aacrjournals.org

106. Lin X et al. "Effect of flaxseed supplementation on prostaticcarcinoma in transgenic mice." Urology. 60, 5:919-24, 2002. http://www.goldjournal.net/

107. Duncan AM. "The role of nutrition in the prevention of breastcancer." AACN Clin Issues. 15, 1:119-35, 2004.

108. Jho DH et al. "Eicosapentaenoic acid supplementation reduces tumorvolume and attenuates cachexia in a rat model of progressive non-metastasizingmalignancy." JPEN J Parenter Enteral Nutr. 26, 5:291-7, 2002.

109. Nkondjock A, Ghadirian P. "Intake of specific carotenoids andessential fatty acids and breast cancer risk in Montreal, Canada." Am JClin Nutr. 79, 5:857-64, 2004. www.ajcn.org

110. Wasser SP. "Medicinal mushrooms as a source of antitumor andimmunomodulating polysaccharides" Appl Microbiol Biotechnol. 60,3:258-74, 2002.

111. Borchers AT, Keen CL, Gershwin ME. "Mushrooms, tumors and immunity:an update." Exp Biol Med (Maywood). 229, 5:393-406, 2004. www.ebmonline.org

112. Jiang J et al. "Ganoderma lucidum inhibits proliferation andinduces apoptosis in human prostate cancer cells PC-3." Int J Oncol.24, 5:1093-9, 2004. www.erlbaum.com/Journals/journals/NC/nc.htm

113. Wachtel-Galor S, Tomlinson B, Benzie IF. "Ganoderma lucidum("Lingzhi"), a Chinese medicinal mushroom: biomarker responses in acontrolled human supplementation study." Br J Nutr. 91, 2:263-9,2004. www.cabi-publishing.org/journals/bjn

114. Ng ML, Yap AT. "Inhibition of human colon carcinoma development bylentinan from shiitake mushrooms (Lentinus edodes)." J Altern Comp Med.8, 5:581-9, 2002. www.liebertpub.com

115. deVere White RW et al. "Effects of a mushroom mycelium extract onthe treatment of prostate cancer." Urology. 60, 4:640-4, 2002. http://www.goldjournal.net/

116. Ohno N et al. "Antitumor beta glucan from the cultured fruit bodyof Agaricus blazei." Biol Pharm Bull. 24, 7:820-8, 2001.

117. Oshiman K et al. "Orally administered beta-1,6-D-polyglucoseextracted from Agaricus blazei results in tumor regression in tumor-bearingmice." Planta Med. 68, 7:610-4, 2002.

118. Barbisan LF et al. "Effects of crude extracts of Agaricus blazei onDNA damage and on rat liver carcinogenesis induced by diethylnitrosamine." GenetMol Res. 2, 3:295-308, 2003.

119. Ahn WS et al. "Natural killer cell activity and quality of lifewere improved by consumption of a mushroom extract, Agaricus blazei MurillKyowa, in gynecological cancer patients undergoing chemotherapy." Int JGynecol Cancer. 14, 4:589-94, 2004.

120. Mayell M. "Maitake extracts and their therapeutic potential." AlternMed Rev. 6, 1:48-60, 2001. www.thorne.com/altmedrev

121. Kodama N et al. "Effects of D-Fraction, a polysaccharide fromGrifola frondosa on tumor growth involve activation of NK cells." BiolPharm Bull. 25, 12:1647-50, 2002.

122. Kodama N, Murata Y, Nanba H. "Administration of a polysaccharidefrom Grifola frondosa stimulates immune function of normal mice." J MedFood. 7, 2:141-5, 2004. www.liebertpub.com

123. Kodama N, Komuta K, Nanba H. "Effect of Maitake (Grifola frondosa)D-Fraction on the activation of NK cells in cancer patients." J Med Food.6, 4:371-7, 2003. www.liebertpub.com

124. Kodama N, Komuta K, Nanba H. "Can maitake MD-fraction aid cancerpatients?" Altern Med Rev. 7, 3:236-9, 2002. www.thorne.com/altmedrev

125. Lin H et al. "Maitake beta-glucan MD-fraction enhances bone marrowcolony formation and reduces doxorubicin toxicity in vitro." IntImmunopharmacol. 4:91-9, 2004. www.elsevier.com/locate/intimp

126. Uno K et al. "Active Hexose Correlated Compound (AHCC) improvesimmunological parameters and performance status of patients with solidtumors." Biotherapy. 14, 3:303-9, 2000. www.kluweronline.com/issn/0921-299X/current.

127. Yagita A et al. "H-2 haplotype-dependent serum IL-12 production intumor-bearing mice treated with various mycelial extracts." In Vivo.16, 1:49-54, 2002.

128. Matsui Y et al. "Improved prognosis of postoperative hepatocellularcarcinoma patients when treated with functional foods: a prospective cohortstudy." J Hepatol. 37, 1:78-86, 2002. www.jhep-elsevier.com

129. Jiang D. "Clinical observation of stage M1 malignant tumors treatedwith the combination of chemotherapy and AHCC." 12th InternationalSymposium of AHCC Research Association, July 24-25, 2004.

130. Hong SJ et al. "The effect of Genistein Combined Polysaccharide(GCP) and Active Hexose Correlated Compound (AHCC) mixture, GAC (Angiogen), onthe reduction of side effects and the improvement of quality of life in prostatecancer patients with androgen suppression." 12th International Symposium ofAHCC Research Association, July 24-25, 2004.

131. Ghafar MA et al. "Regression of prostate cancer followingadministration of Genistein Combined Polysaccharide (GCP), a nutritionalsupplement: a case report." J Altern Comp Med. 8, 4:493-7, 2002. www.liebertpub.com

132. Bemis DL et al. "A concentrated aglycone isoflavone preparation(GCP) that demonstrates potent anti-prostate cancer activity in vitro and invivo." Clin Cancer Res. 10, 15:5282-92, 2004.

133. Hong F et al. "Mechanism by which orally administeredbeta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonalantibodies in murine tumor models." J Immunol. 173:797-806, 2004.

134. Pugh N et al. "Isolation of three high molecular weightpolysaccharide preparations with potent immunostimulatory activity fromSpirulina platensis, aphanizomenon flos-aquae and Chlorella pyrenoidosa." PlantaMed. 67, 8:737-42, 2001.

135. Justo GZ, Silva MR, Queiroz ML. "Effects of the green algaeChlorella vulgaris on the response of the host hematopoietic system tointraperitoneal ehrlich ascites tumor transplantation in mice." ImmunopharmacolImmunotoxicol. 23, 1:119-32, 2001. www.dekker.com/servlet/product/productid/IPH

136. Thomson M, Ali M. "Garlic [Allium sativum]:a review of itspotential use as an anti-cancer agent." Curr Cancer Drug Targets. 3,1:67-81, 2003.

137. Das S. "Garlic--A natural source of cancer preventivecompounds." Asian Pac J Cancer Prev. 3, 4:305-11, 2002.

138. Oommen S et al. "Allicin (from garlic) induces caspase-mediatedapoptosis in cancer cells." Eur J Pharmacol. 485, 1-3:97-103, 2004.

139. Berges R et al. "Comparison of the chemopreventive efficacies ofgarlic powders with different alliin contents against aflatoxin B1carcinogenicity in rats." Carcinogenesis. Epub ahead of print. June3, 2004. http://carcin.oupjournals.org

140. Tilli CM et al. "The garlic-derived organosulfur component ajoenedecreases basal cell carcinoma tumor size by inducing apoptosis." ArchDermatol Res. 295, 3:117-23, 2003.

141. Sundaresan S, Subramanian P. "S-allylcysteine inhibits circulatorylipid peroxidation and promotes antioxidants in N-nitrosodiethylamine-inducedcarcinogenesis." Pol J Pharmacol. 55, 1:37-42, 2003.

142. Lu HF et al. "Diallyl disulfide (DADS) induced apoptosis undergocaspase-3 activity in human bladder cancer T24 cells." Food Chem Tox.42, 10:1543-52, 2004. www.elsevier.nl/locate/foodchemtox

143. Aggarwal BB, Kumar A, Bharti AC. "Anticancer potential of curcumin:preclinical and clinical studies." Anticancer Res. 23, 1A:363-98,2003. www.geocities.com/Athens/Rhodes/8729/iiar/iiar.htm

144. Polasa K et al. "Inhibition of B(a)P induced strand breaks inpresence of curcumin." Mut Res. 557, 2:203-13, 2004. www.mutationresearch.com

145. Van Erk MJ et al. "Time- and dose-dependent effects of curcumin ongene expression in human colon cancer cells." J Carcinog. 3, 1:8,2004.

146. Gao C et al. "[Study on the effects of curcumin onangiogenesis.]" Zhong Yao Cai. 26, 7:499-502, 2003.

147. Radhakrishna Pillai G et al. "Induction of apoptosis in human lungcancer cells by curcumin." Cancer Lett. 208, 2:163-70, 2004. www.elsevier.com/locate/canlet

148. Kienle GS et al. "Mistletoe in cancer--a systematic review oncontrolled clinical trials." Eur J Med Res. 8, 3:109-19, 2003.

149. Schumacher K et al. "Influence of postoperative complementarytreatment with lectin-standardized mistletoe extract on breast cancer patients.A controlled epidemiological multicentric retrolective cohort study." AnticancerRes. 23, 6D:5081-7, 2003. www.geocities.com/Athens/Rhodes/8729/iiar/iiar.htm

150. Piao BK et al. "Impact of complementary mistletoe extract onquality of life in breast, ovarian and non-small cell lung cancer patients. Aprospective randomized controlled clinical trial." Anticancer Res.24, 1:303-9, 2004. www.geocities.com/Athens/Rhodes/8729/iiar/iiar.htm

151. Slattery ML et al. "Plant foods, fiber and rectal cancer." AmJ Clin Nutr. 79, 2:274-81, 2004. www.ajcn.org

152. Pelucchi C et al. "Fibre intake and prostate cancer risk." IntJ Cancer. 109, 2:278-80, 2004. www3.interscience.wiley.com

153. Holmes MD et al. "Dietary carbohydrates, fiber and breast cancerrisk." Am J Epidemiol. 159, 8:732-9, 2004. www.aje.oupjournals.org.

154. Rock CL et al. "Effects of a high-fiber, low-fat diet interventionon serum concentrations of reproductive steroid hormones in women with a historyof breast cancer." J Clin Oncol. 22, 12:2379-87, 2004.